Table 1.
NSCLC patient baseline characteristics
| N = 23 | |
|---|---|
| Sex | |
| Female | 12 (52.2%) |
| Male | 11 (47.8%) |
| Age (median; interquartile range) | |
| 60.0 (53.0⎼67.0) | |
| Drinking history | |
| Current | 5 (21.8%) |
| Former | 1 (4.3%) |
| Non-drinking | 17 (73.9%) |
| Smoking history | |
| Current | 3 (13.0%) |
| Former | 2 (8.7%) |
| Nonsmoker | 18 (78.3%) |
| Lung lobe | |
| Left | 6 (26.1%) |
| Right | 17 (73.9%) |
| Stage | |
| Ⅰ | 7 (30.4%) |
| Ⅱ | 6 (26.1%) |
| Ⅲ | 10 (43.5%) |
| TNM | |
| T T1 | 7 (30.4%) |
| T2 | 7 (30.4%) |
| T3 | 4 (17.4%) |
| T4 | 5 (21.8%) |
| N N0 | 14 (60.9%) |
| N1 | 3 (13.0%) |
| N2 | 6 (26.1%) |
| EGFR mutation types | |
| EGFR (E746-A750del) | 14 (60.9%) |
| EGFR (L858R) | 9 (39.1%) |
| Sensitivity to Adjuvant TKI Therapy | |
| Sensitive | 14 (60.9%) |
| Resistant | 9 (39.1%) |
Abbreviations: NSCLC non–small cell lung cancer, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor